| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | VACWR034 |
| Uniprot No | P18378 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-88aa |
| 氨基酸序列 | MLAFCYSLPNAGDVIKGRVYEKDYALYIYLFDYPHFEAILAESVKMHMDRYVEYRDKLVGKTVKVKVIRVDYTKGYIDVNYKRMCRHQ |
| 预测分子量 | 11.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VACWR034重组蛋白的模拟参考文献示例(注：VACWR034为痘苗病毒Western Reserve株的假定蛋白编号，以下内容为虚构示例，仅供格式参考)：
---
1. **标题**: *Functional characterization of VACWR034 recombinant protein in vaccinia virus immune evasion*
**作者**: Smith J, et al.
**摘要**: 本研究在大肠杆菌中表达并纯化了VACWR034重组蛋白，证实其通过抑制宿主NF-κB信号通路削弱先天免疫应答，提示其在痘苗病毒逃逸宿主防御中的关键作用。
2. **标题**: *Structural analysis and epitope mapping of VACWR034 protein for serological diagnostics*
**作者**: Chen L, et al.
**摘要**: 通过X射线晶体学解析VACWR034蛋白的三维结构，并鉴定其B细胞线性表位，证明该重组蛋白可作为痘苗病毒感染后特异性抗体检测的靶抗原。
3. **标题**: *VACWR034 recombinant protein as a subunit vaccine candidate against orthopoxviruses*
**作者**: Gonzalez R, et al.
**摘要**: 评估VACWR034重组蛋白联合佐剂在小鼠模型中的免疫原性，结果显示其可诱导中和抗体及Th1型细胞免疫，为广谱正痘病毒疫苗开发提供潜在候选。
---
注：实际研究中VACWR034可能需结合具体基因功能命名(如A56R等)，建议通过PubMed等数据库以“VACV WR034”或“vaccinia virus WR034”为关键词检索最新文献。
**Background of VACWR034 Recombinant Protein**
VACWR034 is a gene encoded by the vaccinia virus (VACV), a member of the *Poxviridae* family, historically used in smallpox vaccines and extensively studied as a model for viral replication and host-pathogen interactions. The VACWR034 protein, though not fully characterized, is hypothesized to play a role in viral replication, immune evasion, or modulation of host cell processes. Its recombinant form is generated via molecular cloning, where the VACWR034 gene is inserted into expression vectors (e.g., bacterial, mammalian, or insect cell systems) to produce purified protein for functional and structural studies.
VACWR034 is classified as a late viral protein, suggesting its expression occurs during the later stages of the viral life cycle. Bioinformatics analyses predict conserved domains or motifs that may interact with host immune signaling pathways, such as NF-κB or interferon responses, which poxviruses often target to suppress antiviral defenses. Recombinant VACWR034 enables researchers to study its biochemical properties, including enzymatic activity, protein-protein interactions, and antigenicity. This is critical for understanding its role in viral pathogenesis and identifying potential therapeutic targets.
Interest in VACWR034 also stems from its potential application in vaccine development. Recombinant poxviral proteins are explored as subunit vaccine candidates or components of vectored vaccines against infectious diseases and cancer. Additionally, studying VACWR034 may shed light on the evolutionary adaptation of poxviruses, aiding in preparedness against emerging poxviral threats. Current research focuses on resolving its crystal structure, mapping functional domains, and evaluating its immunogenicity in preclinical models. Challenges include elucidating its precise mechanism and reconciling in vitro findings with in vivo viral behavior.
×
